Phase 3
Completed N=366
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Source: ClinicalTrials.gov NCT04327661 ↗
Enrolled (actual)
366
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcomePrimary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 22; 24; 54 Participants
◆ Published Evidence
Emerging
8citations · ~8 / year
Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study.
Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Linked Publications (2)
-
Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study.
-
Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevention of Vomiting Measured by Vomiting Assessment (VA) |
22; 24; 54 | — |
Eligibility Criteria
Inclusion Criteria
- History of motion sickness
- Age 18-75
Exclusion Criteria
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Data sourced from ClinicalTrials.gov (NCT04327661) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.